Ke-jun Liu

Dongguan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Editorial: EGFR-targeted therapy in lung cancer: unraveling molecular regulation, overcoming resistance, and advancing precision clinical practice.

Editorial: EGFR-targeted therapy in lung cancer: unraveling molecular regulation, overcoming resistance, and advancing precision clinical practice.

Journal: Frontiers in molecular biosciences

Published: July 13, 2026

Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Journal: The Journal of international medical research

Published: December 16, 2025

Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer.

Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer.

Journal: Clinical Medicine Insights. Oncology

Published: October 06, 2025

Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.

Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.

Journal: Translational lung cancer research

Published: June 19, 2025

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement.

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement.

Journal: Cancer medicine

Published: April 23, 2025

The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis.

The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis.

Journal: Science progress

Published: March 19, 2025

Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients.

Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients.

Journal: Translational lung cancer research

Published: April 24, 2024

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 31, 2023

Investigation of the feasibility of synthetic MRI in the differential diagnosis of non-keratinising nasopharyngeal carcinoma and benign hyperplasia using different contoured methods for delineation of the region of interest.

Investigation of the feasibility of synthetic MRI in the differential diagnosis of non-keratinising nasopharyngeal carcinoma and benign hyperplasia using different contoured methods for delineation of the region of interest.

Journal: Clinical radiology

Published: February 04, 2020

Targeted therapy of multiple liver metastases after resected solitary gastric metastasis and primary pulmonary adenocarcinoma.

Targeted therapy of multiple liver metastases after resected solitary gastric metastasis and primary pulmonary adenocarcinoma.

Journal: Oncotarget

Published: March 10, 2016

A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer.

A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer.

Journal: Oncotarget

Published: April 29, 2015

Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: January 01, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026